Clinical Trials · NCT03716115

Therapeutic Approaches to Malnutrition Enteropathy

CompletedPhase 2Teduglutide (Approved)
Phase
Phase 2
Recruitment status
Completed
Sponsor
Queen Mary University of London
Enrollment
125
Start date
May 2020
Locations
3 sites, Zambia, Zimbabwe
Primary endpoint
Composite measure of concentration of three faecal inflammatory markers
View Teduglutide compound reference